Exenatide long-acting - AstraZeneca

Drug Profile

Exenatide long-acting - AstraZeneca

Alternative Names: Bydureon; BYDUREON BCise; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 23 Oct 2017 US FDA approves exenatide long-acting (BYDUREON® BCise™) for the treatment of Type-2 diabetes mellitus in USA
  • 14 Sep 2017 Adverse events data from a phase III trial in Type-2 diabetes mellitus released by AstraZeneca
  • 11 Sep 2017 Efficacy data from the phase III DURATION-7 trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top